Table 8.
Length of stay of very severe and non–severe pneumonia in hospital in low– and middle–income countries
| Country, year | Description | Length of stay (SD) days | Sample size |
|---|---|---|---|
|
Very severe pneumonia |
|||
| Viet Nam, 2010 [18] |
Very severe pneumonia |
6.4(2.7) |
26 |
| Confirmed very severe pneumonia |
5.8 (3.0) |
44 |
|
| Colombia, 2013 [27] |
ICU |
13.0 (6.0–14.0) |
43 |
| South Africa, 2011 [33] |
ICU |
9.4 |
46 |
| ICU |
10.5 |
93 |
|
| South Africa, 2012 [22] |
ICU |
14.4(10.3–18.5) |
7 |
| Pakistan, 2008 [19] |
Time spend at health facility for very severe pneumonia |
3.9 |
35 |
| Argentina, 2012† |
Very severe pneumonia |
8.9 |
– |
| Unilateral focal pneumonia without complications |
17.2 |
– |
|
| Multifocal pneumonia without complications |
11.5 |
– |
|
| Brazil, 2011* |
Public health system |
6.9 |
– |
| Supplementary health system |
6 |
– |
|
| Median (IQR) |
9.2 (6.1–12.6) |
||
|
Non severe pneumonia |
|||
| Pakistan, 2008 [19] |
Time spend at health facility for pneumonia |
0.3 |
41 |
| South Africa, 2012 [22] |
Short stay |
1.4 (1.3–1.6) |
338 |
| Median (IQR) | 0.9 (0.3–1.4) |
ICU – intensive care unit, IQR – interquartile range
*Unpublished data.
†Note added in proof: The data from this study are unpublished but the data on the length of stay are published in Giglio ND, Cane AD, Micone P, Gentile A. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina. Vaccine. 2010;28:2302-10. Medline:20064478.